目的 探討纈沙坦膠囊聯(lián)合賴諾普利膠囊治療原發(fā)性高血壓的臨床療效。方法 選取2016年3月-2017年2月如皋市中醫(yī)院收治的原發(fā)性高血壓患者142例為研究對(duì)象，采取隨機(jī)分組法將所有患者分為對(duì)照組和治療組，每組各71例。對(duì)照組晨起空腹口服賴諾普利膠囊，10 mg/次，1次/d。治療組在對(duì)照組的基礎(chǔ)上晨起口服纈沙坦膠囊，80 mg/次，1次/d。兩組患者均連續(xù)治療8周。觀察兩組的臨床療效，比較兩組的血壓情況。結(jié)果 治療后，對(duì)照組和治療組總有效率分別為87.32%、97.18%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療4、6、8周后，兩組收縮壓（SBP）和舒張壓（DBP）均顯著降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 纈沙坦膠囊聯(lián)合賴諾普利膠囊治療原發(fā)性高血壓具有較好的療效，能顯著降低SBP和DBP，安全性較好，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To observe the clinical effect of Valsartan Capsules combined with Lisinopril Capsules in treatment of primary hypertension. Methods Patients (142 cases) with primary hypertension in Rugao Hospital of Traditional Chinese Medicine from March 2016 to February 2017 were randomly divided into control and treatment groups, and each group had 71 cases. Patients in the control group were po administered with Lisinopril Capsules at the morning empty stomach, 10 mg/time, once daily. Patients in the treatment group were po administered with Valsartan Capsules at the morning empty stomach on the basis of the control group, 80 mg/time, once daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacies were evaluated, and the blood pressure in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 87.32% and 97.18%, respectively, and there was difference between two groups (P<0.05). After treatment, the levels of SBP and DBP in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Valsartan Capsules combined with Lisinopril Capsules has clinical curative effect in treatment of primary hypertension, can significantly decrease the level of SBP and DBP, with good safety, which has a certain clinical application value.